Four Houston entrepreneurs have teamed up to create a program based on each of their expertise that provides a launch pad for aspiring startup founders. Getty Images

For some aspiring startup founders, the biggest thing holding them back is not knowing where to start. A group of former founders and mentors are teaming up to create that first step.

"A few months ago it struck me that maybe there was a gap in the market between the aspiring entrepreneur," says Steve Jennis, "and the accelerator or incubator program."

Jennis, who's a founder, consultant, and mentor in Houston, tapped a few of his fellow founder-mentors to create Founder's Compass, an online masterclass for people who have a business idea but don't know what to do next. Along with Jennis, founder of JCG and PrismTech, the program was created by Brittany Barreto, founder of Pheramor and Femtech Focus; Leela Madan, founder of Madan Law; and Catherine Brown, founder of ExtraBold Sales.

"We thought that the four of us could put together a masterclass comprising of four modules — each module relates to the skill set that we are individually bringing," Jennis tells InnovationMap. "All together, we're representing a framework for new entrepreneurs to get a kickstart to their business and help them with the next step of their journey — whatever that may be."

The four modules will be presented in virtual, interactive classes lasting three hours each and offered in two different ways each month. Students can register for a two-day option — six hours on a Friday followed by another six hours on a Saturday — or a four-week option — three hours on a weeknight once a week for four weeks.

The four modules will cover the following:

  • Validating your business concept and MVP product-market fit (led by Jennis)
  • Customer development, feedback, and target market definition (led Brown)
  • Protecting your intellectual property and managing your business risk (led by Madan)
  • Engaging with the innovation ecosystem and preparing to fundraise (led by Barreto)
Jennis says the program is not intended to be competitive with accelerators, rather Founder's Compass can act as a feeder into these programs. This is why, Jennis says, the masterclass is set up to be relatively cheap at $100 an hour — or $1,200 for the full program.
"We wanted something that was much more convenient, readily available, and easily affordable, so that's why we settled on the two-day or four-evening format to give people something that they didn't have to think about for months," Jennis says. "We saw an opportunity here — not just to be another accelerator — but to be something for people in the game."

Registration for Founder's Compass is open now for September and October, and participants who sign up before August 1 will receive half off — making the course just $600.

The latest Houston innovation news includes a name for the burgeoning Texas A&M University campus in the Texas Medical Center. Photo courtesy of TAMU

Houston startup raises $10M, A&M names TMC campus, and more innovation news

short stories

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks. From a Texas university naming its burgeoning new campus to a Houston SaaS startup with fresh funds, here are some short stories in Houston innovation.

ThoughtTrace raises $10M series B

ThoughtTrace has received investment from Chevron Technology Ventures. Photo via thoughttrace.com

ThoughtTrace Inc., a Houston-based software-as-a-service startup closed a $10 million series B round led by Canadian venture capital fund McRock Capital with contribution from Houston-based Chevron Technology Ventures.

"Chevron Technology Ventures (CTV) pursues externally-developed technologies and new business solutions that have the potential to enhance the way Chevron produces and delivers affordable, reliable and ever-cleaner energy," says Barbara Burger, president of CTV, in a release. "ThoughtTrace fits that mandate with the potential to automate the complex, time-consuming, and document-intensive workflows required for our ongoing business operations."

ThoughtTrace's software quickly analyzes documents and contracts and produces results at a fraction of the cost and time of traditional methods. With the fundraising deal, Scott MacDonald, McRock's co-founder and managing partner, will join ThoughtTrace's Board of Directors.

"We are extraordinarily excited to have both McRock and Chevron join the team. McRock brings a great background in the industrial space, which we see as a great fit. In the case of Chevron, they went from being a new customer in 2019 to an investor in 2020," says Nick Vandivere, ThoughtTrace CEO, in a release.

"With the new capital raise, ThoughtTrace will accelerate its investment in creating AI with unparalleled speed and accuracy, grow strategic partnerships and platform integrations, and add to its existing team of talented professionals, all of which will bring further value to the growing ThoughtTrace customer-base," Vandivere continues.

Texas A&M names its Texas Medical Center campus

The new campus will be called Texas A&M Innovation Plaza. Photo courtesy of Texas A&M University System

After announcing its plans for a $546 million medical complex in Houston's Texas Medical Center in February, Texas A&M University has released the name of the 5-acre campus rising at the intersection of Holcombe Boulevard and Main Street: Texas A&M Innovation Plaza.

The project will be completed in phases. The first phase, which will open later this year, is a renovation of an 18-floor building at 1020 Holcombe Blvd., which will to be the new home for EnMed, a dual degree program that produces both a master's in engineering and a medical degree.

"EnMed is just the first example of innovation that Texas A&M System intends to bring to the Texas A&M Innovation Plaza," says Chancellor John Sharp in a news release. "We are excited to have such a visible location in the Texas Medical Center."

Rice Business Plan Competition lays out virtual plans

The competition must go on. Photo via rbpc.rice.edu

This year's Rice Business Plan Competition, which was planned for March 26 to 28, was canceled due to COVID-19, but the Rice Alliance for Technology and Entrepreneurship has decided to offer up an alternative: A virtual RBPC. Forty two student teams will compete over three virtual events.

  • Elevator Pitch Competition on June 17 (Open to the public): Each team will deliver 60-second pitches.
  • Round 1 on June 18 (Open to startups and judges only ): Each team will deliver 10-minutes to pitch to a panel of judges followed by Q&A.
  • Live finals on June 19 (open to the public): The seven finalists will pitch to the judges, and following a round of questions from judges, the winners and prizes will be announced.

Two health care educational institutions team up for new program

Xavier University and Baylor College of Medicine have launched a collaborative medical track. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Louisiana's Xavier University and Baylor College of Medicine in Houston have joined forces to allow Xavier students a smooth transition into Baylor's graduate programs. Xavier students, including traditionally underrepresented minorities — according to a press release — will have the opportunity to apply for the program in November. Three students will be selected for the program, which facilitates acceptance into the medical school.

"Our commitment at Baylor College of Medicine to diversity and inclusion creates the best environment for success across our mission areas of healthcare, research, education and community outreach," says Dr. Paul Klotman, president, CEO and executive dean of Baylor College of Medicine, in the release. "This important collaboration with Xavier University will strengthen this commitment, and I look forward to welcoming students from this new partnership into the Baylor family."

Klotman continues to express how inclusiveness is a priority for BCM and for this partnership.

"We live in a world where healthcare is changing and evolving," says Dr. Anne McCall, provost and senior vice president for Academic Affairs at Xavier, in the release. "This partnership will further equip our students with the diverse tools and training that they'll need to foster equity in the medical field and compete on an international level."

University of Houston begins offering virtual tours for perspective students

Potential UH Cougars can get the 411 on campus via a virtual tour tool. Photo via uh.edu

Before COVID-19 sent everyone home and canceled gatherings, classes, and events across the world, the University of Houston was already working on a way for potential students to tour and learn more about the campus. Now, in light of the pandemic, UH has released this virtual tour offering complete with live interaction from UH student ambassadors.

"I'm really excited about the live component we just added because prospective students can ask questions just like during a face-to-face campus tour and that interaction is invaluable," says Mardell Maxwell, executive director of UH Admissions, in a release. "UH is so committed to access, and we see this as a great opportunity not only for students in Houston and Texas, but for those coming from out of state. We are opening up access to campus across the world."

Anyone can sign up for a tour online through the university's website.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.